Carnegie Investment Bank

Occlutech, established in 2003, is a European company focused on developing and manufacturing cardiac occlusion devices and vascular implants. The company aims to enhance the quality of life for individuals with heart conditions by creating innovative products for structural heart and interatrial shunt treatment. Utilizing advanced technology and proprietary expertise, Occlutech has introduced a range of unique medical devices designed to improve patient outcomes in cardiac care.

Doktor.se is a digital healthcare company based in Sweden that aims to enhance access to healthcare services. It operates several offices across the country and is experiencing rapid growth. The company employs experienced specialist nurses, doctors, and psychologists who provide quick and effective care to its members. Doktor.se offers a range of services, including counseling, appointment booking, distance care, prescriptions, and referrals, all managed through its app for a seamless experience. As an approved healthcare provider, Doktor.se ensures that all counseling and services are delivered by certified healthcare professionals. In addition to digital consultations, the company also operates physical primary care facilities, allowing it to address a wide array of healthcare needs and relieve pressure on traditional care systems.

Doktor.se is a digital healthcare company based in Sweden that aims to enhance access to healthcare services. It operates several offices across the country and is experiencing rapid growth. The company employs experienced specialist nurses, doctors, and psychologists who provide quick and effective care to its members. Doktor.se offers a range of services, including counseling, appointment booking, distance care, prescriptions, and referrals, all managed through its app for a seamless experience. As an approved healthcare provider, Doktor.se ensures that all counseling and services are delivered by certified healthcare professionals. In addition to digital consultations, the company also operates physical primary care facilities, allowing it to address a wide array of healthcare needs and relieve pressure on traditional care systems.

Agilyx is a developer of advanced conversion technologies aimed at promoting a circular economy for plastics, specifically polystyrene and polymethyl methacrylate. The company focuses on transforming post-use plastics into valuable resources, such as oils and chemical substrates, through its comprehensive waste sourcing and processing solutions. By co-founding Cyclyx International, Agilyx collaborates with industry partners to create tailored plastic recovery programs, enhancing the overall plastic recycling ecosystem. This initiative aligns with Agilyx's mission to facilitate the chemical recycling of plastics on a global scale, thereby contributing to a low-carbon economy and enabling the recycling market to effectively manage waste plastics. The majority of Agilyx's revenue is generated from its Cyclyx segment, underscoring its commitment to innovative waste management and recycling practices.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.

Galileo genomics is a Montreal-based private genetics company that conducts research in Quebecers of French descent using cutting-edge technologies, to identify genes that cause disease, thus providing validated targets for creation of innovative and more effective therapies and diagnostics. The Quebec founder population is the largest such population worldwide, which facilitates rapid patient recruiting. Because of the relatively late founding of the population in the 17th century, the relatively small number of founders, rapid early population growth, minimal intermarriage with other groups, and loss of some family lines while others expanded dramatically, the population is among the most homogeneous and has among the highest genetic sharing of all major founder populations.

Agensys is a biotechnology company focused on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates specifically for cancer treatment. The company offers products aimed at addressing various tumors, including those associated with prostate, pancreatic, bladder, kidney, lung, and colon cancers. Founded in 1997 and based in Santa Monica, California, Agensys operates as a subsidiary of Astellas Pharma US, Inc. It is dedicated to providing innovative therapeutic solutions to improve patient outcomes in oncology.

ZoomON's software enables anyone with a browser to view, mark-up, design and collaborate on complex, and simple, graphics. This includes maps, product drawings and product catalogs. Their software cuts across proprietary technologies and unleashes the details anytime, anywhere!